Skip to content
Bending the Curve Trial by Trial
?

Back to Testicular germ cell tumors

References: Testicular germ cell tumors

113 sources cited on this page. Links open the primary source.

  1. Dixon FJ, Moore RA. Testicular tumors; a clinicopathological study. Cancer. 1953;6(3):427-54. PubMedDOI
    CiteLoading…
  2. LI MC, WHITMORE WF Jr, GOLBEY R, GRABSTALD H. Effects of combined drug therapy on metastatic cancer of the testis. JAMA. 1960;174:1291-9. PubMedDOI
    CiteLoading…
  3. ROSENBERG B, VANCAMP L, KRIGAS T. INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE. Nature. 1965;205:698-9. PubMedDOI
    CiteLoading…
  4. Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature. 1969;222(5191):385-6. PubMedDOI
    CiteLoading…
  5. Skakkebæk NE. Possible carcinoma-in-situ of the testis. Lancet. 1972;2(7776):516-7. PubMedDOI
    CiteLoading…
  6. Samuels ML, Johnson DE, Holoye PY. Continuous intravenous bleomycin (NSC-125066) therapy with vinblastine (NSC-49842) in stage III testicular neoplasia. Cancer Chemother Rep. 1975;59(3):563-70. PubMed
    CiteLoading…
  7. Samuels ML, Holoye PY, Johnson DE. Bleomycin combination chemotherapy in the management of testicular neoplasia. Cancer. 1975;36(2):318-26. PubMedDOI
    CiteLoading…
  8. Perlin E, Engeler JE Jr, Edson M, Karp D, McIntire KR, Waldmann TA. The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors. Cancer. 1976;37(1):215-9. PubMedDOI
    CiteLoading…
  9. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977;87(3):293-8. PubMedDOI
    CiteLoading…
  10. Atkin NB, Baker MC. Specific chromosome change, i(12p), in testicular tumours?. Lancet. 1982;2(8311):1349. PubMedDOI
    CiteLoading…
  11. Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol. 1982;128(2):315-20. PubMedDOI
    CiteLoading…
  12. Atkin NB, Baker MC. i(12p): specific chromosomal marker in seminoma and malignant teratoma of the testis?. Cancer Genet Cytogenet. 1983;10(2):199-204. PubMedDOI
    CiteLoading…
  13. Williams SD, Stablein DM, Einhorn LH, Muggia FM, Weiss RB, Donohue JP, et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med. 1987;317(23):1433-8. PubMedDOI
    CiteLoading…
  14. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316(23):1435-40. PubMedDOI
    CiteLoading…
  15. Jewett MA, Kong YS, Goldberg SD, Sturgeon JF, Thomas GM, Alison RE, et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol. 1988;139(6):1220-4. PubMedDOI
    CiteLoading…
  16. Einhorn LH, Williams SD, Loehrer PJ, Birch R, Drasga R, Omura G, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol. 1989;7(3):387-91. PubMedDOI
    CiteLoading…
  17. Read G, Stenning SP, Cullen MH, Parkinson MC, Horwich A, Kaye SB, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol. 1992;10(11):1762-8. PubMedDOI
    CiteLoading…
  18. Loehrer PJ Sr, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995;13(2):470-6. PubMedDOI
    CiteLoading…
  19. Cullen MH, Stenning SP, Parkinson MC, Fossa SD, Kaye SB, Horwich AH, et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol. 1996;14(4):1106-13. PubMedDOI
    CiteLoading…
  20. Sandberg AA, Meloni AM, Suijkerbuijk RF. Reviews of chromosome studies in urological tumors. III. Cytogenetics and genes in testicular tumors. J Urol. 1996;155(5):1531-56. PubMed
    CiteLoading…
  21. de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol. 1997;15(5):1837-43. PubMedDOI
    CiteLoading…
  22. Horwich A, Sleijfer DT, Fosså SD, Kaye SB, Oliver RT, Cullen MH, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol. 1997;15(5):1844-52. PubMedDOI
    CiteLoading…
  23. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15(2):594-603. PubMedDOI
    CiteLoading…
  24. Donohue JP, Foster RS. Retroperitoneal lymphadenectomy in staging and treatment. The development of nerve-sparing techniques. Urol Clin North Am. 1998;25(3):461-8. PubMedDOI
    CiteLoading…
  25. Loehrer PJ Sr, Gonin R, Nichols CR, Weathers T, Einhorn LH. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998;16(7):2500-4. PubMedDOI
    CiteLoading…
  26. Saxman SB, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol. 1998;16(2):702-6. PubMedDOI
    CiteLoading…
  27. Dieckmann KP, Skakkebaek NE. Carcinoma in situ of the testis: review of biological and clinical features. Int J Cancer. 1999;83(6):815-22. PubMedDOI
    CiteLoading…
  28. Fosså SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ, et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol. 1999;17(4):1146. PubMedDOI
    CiteLoading…
  29. De Santis M, Bokemeyer C, Becherer A, Stoiber F, Oechsle K, Kletter K, et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol. 2001;19(17):3740-4. PubMedDOI
    CiteLoading…
  30. Dixon FJ, Moore RA. Testicular tumors. A clinicopathological study. 1953. J Urol. 2002;167(2 Pt 2):896-918; discussion 919. PubMed
    CiteLoading…
  31. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci U S A. 2002;99(7):4592-5. PubMedDOI
    CiteLoading…
  32. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002;20(22):4448-52. PubMedDOI
    CiteLoading…
  33. Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R, et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol. 2003;21(6):1101-6. PubMedDOI
    CiteLoading…
  34. Donohue JP. Evolution of retroperitoneal lymphadenectomy (RPLND) in the management of non-seminomatous testicular cancer (NSGCT). Urol Oncol. 2003;21(2):129-32. PubMedDOI
    CiteLoading…
  35. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21(8):1513-23. PubMedDOI
    CiteLoading…
  36. Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol. 2003;21(17):3310-7. PubMedDOI
    CiteLoading…
  37. De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol. 2004;22(6):1034-9. PubMedDOI
    CiteLoading…
  38. Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol. 2005;23(6):1200-8. PubMedDOI
    CiteLoading…
  39. Kondagunta GV, Bacik J, Donadio A, Bajorin D, Marion S, Sheinfeld J, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005;23(27):6549-55. PubMedDOI
    CiteLoading…
  40. Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005;366(9482):293-300. PubMedDOI
    CiteLoading…
  41. Pico JL, Rosti G, Kramar A, Wandt H, Koza V, Salvioni R, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol. 2005;16(7):1152-9. PubMedDOI
    CiteLoading…
  42. Travis LB, Fosså SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97(18):1354-65. PubMedDOI
    CiteLoading…
  43. Young RH. A brief history of the pathology of the gonads. Mod Pathol. 2005;18 Suppl 2:S3-S17. PubMedDOI
    CiteLoading…
  44. van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodrigus PT, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2006;24(3):467-75. PubMedDOI
    CiteLoading…
  45. Culine S, Kerbrat P, Kramar A, Théodore C, Chevreau C, Geoffrois L, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol. 2007;18(5):917-24. PubMedDOI
    CiteLoading…
  46. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357(4):340-8. PubMedDOI
    CiteLoading…
  47. Karellas ME, Damjanov I, Holzbeierlein JM. ITGCN of the testis, contralateral testicular biopsy and bilateral testicular cancer. Urol Clin North Am. 2007;34(2):119-25; abstract vii. PubMedDOI
    CiteLoading…
  48. Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25(3):247-56. PubMedDOI
    CiteLoading…
  49. Rustin GJ, Mead GM, Stenning SP, Vasey PA, Aass N, Huddart RA, et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol. 2007;25(11):1310-5. PubMedDOI
    CiteLoading…
  50. Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol. 2008;26(18):2966-72. PubMedDOI
    CiteLoading…
  51. Hinz S, Schrader M, Kempkensteffen C, Bares R, Brenner W, Krege S, et al. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol. 2008;179(3):936-40; discussion 940. PubMedDOI
    CiteLoading…
  52. Kanetsky PA, Mitra N, Vardhanabhuti S, Li M, Vaughn DJ, Letrero R, et al. Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet. 2009;41(7):811-5. PubMedDOI
    CiteLoading…
  53. The UK Testicular Cancer Collaboration, Rapley EA, Turnbull C, Al Olama AA, Dermitzakis ET, Linger R, Huddart RA, et al. A genome-wide association study of testicular germ cell tumor. Nat Genet. 2009;41(7):807-10. PubMedDOI
    CiteLoading…
  54. Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stierner U, Solberg A, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol. 2009;27(13):2122-8. PubMedDOI
    CiteLoading…
  55. Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010;28(10):1706-13. PubMedDOI
    CiteLoading…
  56. Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28(30):4649-57. PubMedDOI
    CiteLoading…
  57. Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol. 2011;22(5):1054-1061. PubMedDOI
    CiteLoading…
  58. Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol. 2011;29(16):2178-84. PubMedDOI
    CiteLoading…
  59. Mead GM, Fossa SD, Oliver RT, Joffe JK, Huddart RA, Roberts JT, et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst. 2011;103(3):241-9. PubMedDOI
    CiteLoading…
  60. Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011;29(8):957-62. PubMedDOI
    CiteLoading…
  61. Ehrlich Y, Beck SD, Foster RS, Bihrle R, Einhorn LH. Serum tumor markers in testicular cancer. Urol Oncol. 2013;31(1):17-23. PubMedDOI
    CiteLoading…
  62. Fung C, Fossa SD, Milano MT, Oldenburg J, Travis LB. Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol. 2013;31(30):3807-14. PubMedDOI
    CiteLoading…
  63. Aparicio J, Maroto P, García Del Muro X, Sánchez-Muñoz A, Gumà J, Margelí M, et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol. 2014;25(11):2173-2178. PubMedDOI
    CiteLoading…
  64. Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol. 2014;15(13):1442-1450. PubMedDOI
    CiteLoading…
  65. Horwich A, Fossa SD, Huddart R, Dearnaley DP, Stenning S, Aresu M, et al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer. 2014;110(1):256-63. PubMedDOI
    CiteLoading…
  66. Tandstad T, Ståhl O, Håkansson U, Dahl O, Haugnes HS, Klepp OH, et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol. 2014;25(11):2167-2172. PubMedDOI
    CiteLoading…
  67. Fung C, Fossa SD, Milano MT, Sahasrabudhe DM, Peterson DR, Travis LB. Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study. J Clin Oncol. 2015;33(28):3105-15. PubMedDOI
    CiteLoading…
  68. Litchfield K, Shipley J, Turnbull C. Common variants identified in genome-wide association studies of testicular germ cell tumour: an update, biological insights and clinical application. Andrology. 2015;3(1):34-46. PubMedDOI
    CiteLoading…
  69. Berney DM, Looijenga LH, Idrees M, Oosterhuis JW, Rajpert-De Meyts E, Ulbright TM, et al. Germ cell neoplasia in situ (GCNIS): evolution of the current nomenclature for testicular pre-invasive germ cell malignancy. Histopathology. 2016;69(1):7-10. PubMedDOI
    CiteLoading…
  70. Tandstad T, Ståhl O, Dahl O, Haugnes HS, Håkansson U, Karlsdottir Å, et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol. 2016;27(7):1299-304. PubMedDOI
    CiteLoading…
  71. Kerns SL, Fung C, Monahan PO, Ardeshir-Rouhani-Fard S, Abu Zaid MI, Williams AM, et al. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. J Clin Oncol. 2018;36(15):1505-1512. PubMedDOI
    CiteLoading…
  72. Dieckmann KP, Radtke A, Geczi L, Matthies C, Anheuser P, Eckardt U, et al. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. J Clin Oncol. 2019;37(16):1412-1423. PubMedDOI
    CiteLoading…
  73. Hamilton RJ, Nayan M, Anson-Cartwright L, Atenafu EG, Bedard PL, Hansen A, et al. Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. J Clin Oncol. 2019;37(22):1919-1926. PubMedDOI
    CiteLoading…
  74. National Cancer Institute. Drugs Approved for Testicular Cancer. https://www.cancer.gov/about-cancer/treatment/drugs/testicular. Page shows 'Last updated: May 16, 2019'; accessed 20 October 2026. Source
  75. Hellesnes R, Kvammen Ø, Myklebust TÅ, Bremnes RM, Karlsdottir Á, Negaard HFS, et al. Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era. Int J Cancer. 2020;147(1):21-32. PubMedDOI
    CiteLoading…
  76. Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T, et al. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. J Clin Oncol. 2021;39(14):1553-1562. PubMedDOI
    CiteLoading…
  77. Gillessen S, Sauvé N, Collette L, Daugaard G, de Wit R, Albany C, et al. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. J Clin Oncol. 2021;39(14):1563-1574. PubMedDOI
    CiteLoading…
  78. Hellesnes R, Myklebust TÅ, Fosså SD, Bremnes RM, Karlsdottir Á, Kvammen Ø, et al. Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort. J Clin Oncol. 2021;39(32):3561-3573. PubMedDOI
    CiteLoading…
  79. Fosså SD, Dahl AA, Thorsen L, Hellesnes R, Kiserud CE, Tandstad T, et al. Mortality and Second Cancer Incidence After Treatment for Testicular Cancer: Psychosocial Health and Lifestyle Are Modifiable Prognostic Factors. J Clin Oncol. 2022;40(23):2588-2599. PubMedDOI
    CiteLoading…
  80. Joffe JK, Cafferty FH, Murphy L, Rustin GJS, Sohaib SA, Gabe R, et al. Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST). J Clin Oncol. 2022;40(22):2468-2478. PubMedDOI
    CiteLoading…
  81. Oldenburg J, Berney DM, Bokemeyer C, Climent MA, Daugaard G, Gietema JA, et al. Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(4):362-375. PubMedDOI
  82. Hiester A, Che Y, Lusch A, Kuß O, Niegisch G, Lorch A, et al. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST). Eur Urol. 2023;84(1):25-31. PubMedDOI
    CiteLoading…
  83. Boormans JL, Sylvester R, Anson-Cartwright L, Glicksman RM, Hamilton RJ, Hahn E, et al. Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office. Eur Urol Oncol. 2024;7(3):537-543. PubMedDOI
    CiteLoading…
  84. Dieckmann KP, Belge G. [Testicular Germ Cell Tumours - features and prospects of the novel tumour marker microRNA-371a-3p (M371 test): a narrative review]. Aktuelle Urol. 2024;55(6):510-519. PubMed
    CiteLoading…
  85. Fizazi K, Le Teuff G, Fléchon A, Pagliaro L, Mardiak J, Geoffrois L, et al. Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. J Clin Oncol. 2024;42(28):3270-3276. PubMedDOI
    CiteLoading…
  86. Gleeson JP, Knezevic A, Bromberg M, Patil S, Sheinfeld J, Carver BS, et al. Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease. J Clin Oncol. 2024;42(26):3130-3139. PubMedDOI
    CiteLoading…
  87. Gilligan T, Lin DW, Adra N, Bagrodia A, Feldman DR, Yamoah K, et al. NCCN Guidelines Insights: Testicular Cancer, Version 2.2025. J Natl Compr Canc Netw. 2025;23(4). PubMedDOI
  88. Heidenreich A, Patrikidou A, Tandstad T. Role of Retroperitoneal Lymph Node Dissection in Clinical Stage IIA/B Seminoma: Recommendations from the European Association of Urology Guidelines Panel on Testicular Cancer. Eur Urol. 2025;88(6):540-542. PubMedDOI
    CiteLoading…
  89. Cancer Research UK. Testicular cancer survival statistics. Health professional page. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/testicular-cancer/survival. Page accessed 20 October 2026; no update date seen. Source
  90. ClinicalTrials.gov. NCT00002566 (IT-94, FRE-IT94). Registry record, accessed 20 October 2026. NCT00002566
  91. ClinicalTrials.gov. NCT00003941 (EORTC-30974). Registry record, accessed 20 October 2026. NCT00003941
  92. ClinicalTrials.gov. NCT00104676 (GETUG 13). Registry record, accessed 20 October 2026. NCT00104676
  93. ClinicalTrials.gov. NCT00589537 (TRISST). Registry record, accessed 20 October 2026. NCT00589537
  94. ClinicalTrials.gov. NCT02341989 (SWENOTECA-ABC). Registry record, API v2, accessed 20 October 2026. NCT02341989
  95. ClinicalTrials.gov. NCT02375204 (TIGER, Alliance A031102). Registry record, accessed 20 October 2026. NCT02375204
  96. ClinicalTrials.gov. NCT02582697 (P3BEP, ANZUP 1302). Registry record, API v2, accessed 20 October 2026. NCT02582697
  97. ClinicalTrials.gov. NCT02797626 (PRIMETEST). Registry record, accessed 20 October 2026. NCT02797626
  98. ClinicalTrials.gov. NCT03067181 (COG AGCT1531). Registry record, API v2, accessed 20 October 2026. NCT03067181
  99. ClinicalTrials.gov. NCT05874063 (GIG-T). Registry record, API v2, accessed 20 October 2026. NCT05874063
  100. DailyMed. Bleomycin for injection, Meitheal Pharmaceuticals Inc. (ANDA205030), SPL set id 640602f9-a7df-46f0-a9b1-19c471008bee, version 3, effective 17 April 2026 (text read through the openFDA drug label API). Source
  101. DailyMed. Cisplatin for injection, WG Critical Care, LLC (NDA018057), SPL set id 508496cb-3441-46b3-a4fe-e0d440e6adc6, version 4, effective 24 June 2026 (text read through the openFDA drug label API). Source
  102. DailyMed. Etoposide injection, BluePoint Laboratories (ANDA074529), SPL set id 0dddbe44-b4f4-431f-9011-8a54abbd4cbf, version 2, effective 20 May 2026 (text read through the openFDA drug label API). Source
  103. DailyMed. Ifosfamide for injection, Fresenius Kabi USA, LLC (ANDA076078), SPL set id a311a947-7b78-4226-bfe0-f4aa0be20e27, version 5, effective 9 April 2026 (text read through the openFDA drug label API). Source
  104. European Association of Urology. EAU Guidelines on Testicular Cancer, section 6 Disease management (2026 edition per the download file names on the page). uroweb.org, accessed 20 October 2026. Source
  105. European Association of Urology. EAU Guidelines on Testicular Cancer, section 7 Follow up after curative therapy (2026 edition: the Introduction describes the 2026 guideline as a limited update of the 2024 publication). uroweb.org, accessed 20 October 2026; the page displays no update date. Source
  106. Kerns SL, Dinh PC Jr, Monahan PO, Fung C, Sesso HD, Feldman DR, et al. Cardiovascular disease risk among long-term testicular cancer survivors following contemporary cisplatin-based chemotherapy. J Natl Cancer Inst. 2026 Feb 12 (online ahead of print; no volume or pages assigned, article djag035). PubMedDOI
    CiteLoading…
  107. Mousa A, Amiri A, Kaushal S, Wilson E, Tan I, Hamilton RJ. Secondary leukaemia after testicular germ cell tumour treatment: a systematic review and meta-analysis. BJU Int. 2026;138(3):370-378. PubMedDOI
    CiteLoading…
  108. US Food and Drug Administration. openFDA Drugs@FDA API record for NDA 018057 (cisplatin; Platinol), submission history. Queried 20 October 2026. Source
  109. US Food and Drug Administration. openFDA Drugs@FDA API record for NDA 018768 (etoposide; VePesid), submission history. Queried 20 October 2026. Source
  110. US Food and Drug Administration. openFDA Drugs@FDA API record for NDA 019763 (ifosfamide; Ifex), submission history. Queried 20 October 2026. Source
  111. US Food and Drug Administration. openFDA Drugs@FDA API record for NDA 050443 (bleomycin; Blenoxane), submission history. Queried 20 October 2026. Source
  112. Patrikidou A, Cazzaniga W, Oing C, Berney D, Lobo J, Boormans J, et al. European Association of Urology Guidelines on Testicular Cancer: Summary of the 2026 Guidelines. Eur Urol. 2026;90(2):163-174. PubMedDOI
    CiteLoading…
  113. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Testicular Cancer. Page accessed 20 October 2026; the page displays no update date (its HTTP Last-Modified header and last_modified meta tag read 22 April 2026). Source